Modality
Vaccine
MOA
MDM2i
Target
GIP-R
Pathway
RNA Splicing
HNSCC
Development Pipeline
Preclinical
~Nov 2018
→ ~Feb 2020
Phase 1
~May 2020
→ ~Aug 2021
Phase 2
Nov 2021
Phase 2Current
NCT03801095
450 pts·HNSCC
2021-11→TBD·Active
450 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
P2
Active
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03801095 | Phase 2 | HNSCC | Active | 450 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| AMG-415 | Amgen | Phase 1 | CDK2 | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| Capiglumide | BioNTech | Preclinical | CGRP |